Combined Holdings of VERV in All ARK ETFs
Verve Therapeutics
VERV, a biotechnology company, focuses on developing innovative gene-editing therapies aimed at treating cardiovascular diseases by targeting specific genetic causes. The company generates revenue primarily through research and collaboration agreements, licensing of its technology, and future commercialization of its therapeutic candidates.
Trades of VERV in All Ark ETFs
The ten most recent trades of Verve Therapeutics in all the Ark ETFs ETF.View all trades
Date | Direction | Market Value | % of Position | % of ETF |
|---|---|---|---|---|
| Sep 09, 2024 | Sell | $174 | 0.00% | 0.00% |
| Sep 04, 2024 | Sell | $78 | 0.00% | 0.00% |
| Sep 03, 2024 | Sell | $1,158 | 0.01% | 0.00% |
| Aug 28, 2024 | Sell | $140,886 | 1.60% | 0.01% |
| Aug 27, 2024 | Sell | $415,781 | 4.99% | 0.03% |
| Aug 26, 2024 | Sell | $1,450,721 | 17.23% | 0.10% |
| Aug 23, 2024 | Sell | $91,119 | 0.95% | 0.01% |
| Aug 21, 2024 | Sell | $506,830 | 5.08% | 0.04% |
| Aug 20, 2024 | Sell | $1,392,941 | 13.47% | 0.10% |
| Aug 19, 2024 | Sell | $2,896,581 | 26.20% | 0.21% |